Use: Labeled indications
- INDICATIONS AND USAGE Baclofen tablets USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus…
Full indications and usage US FDA label
INDICATIONS AND USAGE Baclofen tablets USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function.
Baclofen tablets USP may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen tablets USP are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions.
Contraindications
CONTRAINDICATIONS Hypersensitivity to baclofen.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION The determination of optimal dosage requires individual titration. Start therapy at a low dosage and increase gradually until optimum effect is achieved (usually between 40 to 80 mg daily). The following dosage titration schedule is suggested: 5 mg t.i.d. for 3 days 10 mg t.i.d. for 3 days 15 mg t.i.d. for 3 days 20 mg t.i.d. for 3 days Thereafter additional increases may be necessary but the total daily dose should not exceed a maximum of 80 mg daily (20 mg q.i.d.).
The lowest dose compatible with an optimal response is recommended. If benefits are not evident after a reasonable trial period, patients should be slowly withdrawn from the drug (see WARNINGS, Abrupt Drug Withdrawal).
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Tablet: 10 mg
- Film-coated tablet: 10 mg
Registered products in the Philippines
12 products registered with the Food and Drug Administration (FDA) Philippines list Baclofen as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products12
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Bac-10Baclofen | 10 mg TabletAlu/Clear PVDC Blister Pack x 10's Box of 100's | Rx | Hizon Laboratories, Inc.Philippines | Sigma Medical Solution Trading Co. Inc. | DRP-4052 | Aug 13, 2027 | |
BaclisolvBaclofen | 10 mg TabletAlu/PVC Blister Pack x 10’s (Box of 50’s) | Rx | Stallion Laboratories Pvt. Ltd.India | Premier Pharmaceuticals Marketing Corp.Importer: Ambica International Corporation | DRP-10598 | Oct 22, 2031 | |
BaclorBaclofen | 10 mg TabletAlu/PVDC Blister Pack x 10’s (Box of 30’s and 50’s) | Rx | Eskayef Pharmaceuticals LimitedBangladesh | Ambica International CorporationImporter: Ambicare Pharmaceuticals, Inc. | DRP-10509-01 | Oct 8, 2031 | |
Baxan 10Baclofen | 10 mg TabletAlu/PVC Blister Pack x 10's | Rx | Globela Pharma Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-18679 | Dec 8, 2031 | |
FenobacBaclofen | 10 mg TabletAlu/PVDC Blister Pack x 10's (Box of 30's and 50's) | Rx | Eskayef Pharmaceuticals LimitedBangladesh | Ambicare Pharmaceuticals Inc. | DRP-10509 | Oct 8, 2031 | |
LioresalBaclofen | 10 mg TabletBlister Pack x 10's (Box of 50's) | Rx | Novartis Farma S.p.AItaly | Novartis Healthcare Philippines, Inc. | DR-X8065 | Sep 3, 2029 | |
LiosalBaclofen | 10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10 's (Box of 20's and 100's) | Rx | DELTA PHARMA LTD.Bangladesh | BIOMED PHARMA INC. | DR-XY40693 | Feb 25, 2030 | |
LiosalBaclofen | 10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's and 100's) | Rx | Delta Pharma Ltd.Bangladesh | Biomed Pharma Inc. | DRP-17367 | Feb 25, 2030 | |
MyafenBaclofen | 10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's and 100's) | Rx | Delta Pharma Ltd.Bangladesh | The Cathay Yss Distributors Co., IncImporter: Biomed Pharma Inc. | DRP-17367-01 | Feb 25, 2030 | |
SpilogenBaclofen | 10mg TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 30's) | Rx | Celogen Generics Private Ltd.India | Saifen Drugs Philippines, Inc. | DR-XY49342 | Feb 25, 2030 | |
TrilaxantBaclofen | 10 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Yooyoung Pharmaceutical Co., Ltd.Republic of Korea | One Pharma Marketing Inc.Importer: H & B Pharma International Inc. | DR-XY35815 | May 13, 2029 | |
(no brand name)Baclofen | 10 mg TabletAlu/PVdC Blister Pack x 10's (Box of 100's) | Rx | Eskayef Pharmaceuticals limitedBangladesh | One Pharma Marketing, Inc.Importer: Brightwell Marketing and Distributions Inc. | DRP-18452 | Jul 14, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Neonatal Withdrawal Symptoms: Withdrawal symptoms have been reported starting hours to days after delivery in neonates whose mothers were treated with oral baclofen throughout pregnancy. The symptoms of withdrawal in these infants have included increased muscle tone, tremor, jitteriness, and seizure. If the potential benefit justifies the potential risk to the fetus and oral baclofen is continued during pregnancy, gradually reduce the dose and discontinue baclofen before delivery.
If slow withdrawal is not feasible, advise the parents or caregivers of the potential for neonatal withdrawal. Abrupt Drug Withdrawal: Hallucinations and seizures have occurred on abrupt withdrawal of baclofen. Therefore, except for serious adverse reactions, the dose should be reduced slowly when the drug is discontinued.
Impaired Renal Function: Because baclofen is primarily excreted unchanged through the kidneys, it should be given with caution, and it may be necessary to reduce the dosage. Stroke: Baclofen has not significantly benefited patients with stroke. These patients have also shown poor tolerability to the drug. Pregnancy: Baclofen has been shown to increase the incidence of omphaloceles (ventral hernias) in fetuses of rats given approximately 13 times the maximum dose recommended for human use, at a dose which caused significant reductions in food intake and weight gain in dams.
This abnormality was not seen in mice or rabbits. There was also an increased incidence of incomplete sternebral ossification in fetuses of rats given approximately 13 times the maximum recommended human dose, and an increased incidence of unossified phalangeal nuclei of forelimbs and hindlimbs in fetuses of rabbits given approximately 7 times the maximum recommended human dose.
In mice, no teratogenic effects were observed, although reductions in mean fetal weight with consequent delays in skeletal ossification were present when dams were given 17 and 34 times the human daily dose. There are no studies in pregnant women. Baclofen should be used during pregnancy only if the benefit clearly justifies the potential risk to the fetus.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The most common is transient drowsiness (10 to 63%). In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen compared to 36% of those in the placebo group. Other common adverse reactions are dizziness (5 to 15%), weakness (5 to 15%) and fatigue (2 to 4%).
Others reported: Neuropsychiatric: Confusion (1 to 11%), headache (4 to 8%), insomnia (2 to 7%); and, rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure. Cardiovascular: Hypotension (0 to 9%).
Rare instances of dyspnea, palpitation, chest pain, syncope. Gastrointestinal: Nausea (4 to 12%), constipation (2 to 6%); and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool. Genitourinary: Urinary frequency (2 to 6%); and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria.
Other: Instances of rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion. Some of the CNS and genitourinary symptoms may be related to the underlying disease rather than to drug therapy. The following laboratory tests have been found to be abnormal in a few patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar.
Pharmacokinetics
Baclofen is excreted primarily by the kidney in unchanged form and there is relatively large intersubject variation in absorption and/or elimination.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY The precise mechanism of action of baclofen is not fully known. Baclofen is capable of inhibiting both monosynaptic and polysynaptic reflexes at the spinal level, possibly by hyperpolarization of afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect.
Although baclofen is an analog of the putative inhibitory neurotransmitter gamma-aminobutyric acid (GABA), there is no conclusive evidence that actions on GABA systems are involved in the production of its clinical effects. In studies with animals baclofen has been shown to have general CNS depressant properties as indicated by the production of sedation with tolerance, somnolence, ataxia, and respiratory and cardiovascular depression.
Baclofen is rapidly and extensively absorbed and eliminated. Absorption may be dose-dependent, being reduced with increasing doses. Baclofen is excreted primarily by the kidney in unchanged form and there is relatively large intersubject variation in absorption and/or elimination.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Baclofen 10 mg Tablet | ₱10.98–₱15.50Reference ₱13.80 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Baclofen |
| PNF listing | Oral: 10 mg tablet |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Baclofen · Par Health USA, LLC [US FDA-approved label, version 24, August 24, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c17527be-661d-42f5-b6f6-56a681ba7870
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
